

SUPPLEMENTARY TABLE 1. Characteristics of fully vaccinated controls with and without sera among hospitalized veterans — five Veterans Affairs Medical Centers, United States, February 1–September 30, 2021*

Characteristic	No. (%)		p-value [§]
	Vaccinated controls without sera (n = 379)	Vaccinated controls with sera [†] (n = 234)	
Male sex	360 (95.0)	220 (94.0)	0.606
Age, years, median [IQR]	71 [64–76]	73 [65–78]	0.095
Age, yrs			
18–49	11 (2.9)	8 (3.4)	0.239
50–64	91 (24.0)	45 (19.2)	
65–74	160 (42.2)	91 (38.9)	
75–84	75 (19.8)	68 (29.1)	
≥85	42 (11.1)	22 (9.4)	
Race/Ethnicity			
Black, non-Hispanic	200 (52.8)	102 (43.6)	0.915
White, non-Hispanic	140 (36.9)	110 (47.0)	
Hispanic, any race	30 (7.9)	14 (6.0)	
Other, non-Hispanic [¶]	9 (2.4)	8 (3.4)	
COVID-19 fully vaccinated**			
Pfizer-BioNTech	243 (64.1)	144 (61.5)	0.521
Moderna	136 (35.9)	90 (38.5)	

Abbreviation: BAU = binding antibody units.

* Serum specimens collected during March 22–August 31, 2021.

[†] Excluded 25 controls with anti-nucleocapsid antibodies (>11.8 BAU/mL), suggesting a prior SARS-CoV-2 infection.

[§] Testing for statistical significance was conducted using Wilcoxon rank-sum test for median age; all others used chi-square tests. Statistical significance was set at $p < 0.05$.

[¶] Included non-Hispanic American Indian and Alaska Native, non-Hispanic Asian and Pacific Islander, non-Hispanic multiple race, or non-Hispanic other race.

** COVID-19 vaccination status includes unvaccinated, defined as no receipt of any SARS-CoV-2 vaccine, and fully vaccinated, defined as receipt of both doses of an mRNA (Pfizer-BioNTech or Moderna) ≥14 days before the first SARS-CoV-2 test performed within 14 days before admission or during the first 72 hours of hospitalization.